AU2001276608A1 - Sustained release formulations for growth hormone secretagogues - Google Patents

Sustained release formulations for growth hormone secretagogues

Info

Publication number
AU2001276608A1
AU2001276608A1 AU2001276608A AU7660801A AU2001276608A1 AU 2001276608 A1 AU2001276608 A1 AU 2001276608A1 AU 2001276608 A AU2001276608 A AU 2001276608A AU 7660801 A AU7660801 A AU 7660801A AU 2001276608 A1 AU2001276608 A1 AU 2001276608A1
Authority
AU
Australia
Prior art keywords
sustained release
growth hormone
release formulations
hormone secretagogues
secretagogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001276608A
Inventor
Mary Tanya Am Ende
William John Curatolo
Scott Max Herbig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU2001276608A1 publication Critical patent/AU2001276608A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
AU2001276608A 2000-08-30 2001-08-08 Sustained release formulations for growth hormone secretagogues Abandoned AU2001276608A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22907400P 2000-08-30 2000-08-30
US60/229,074 2000-08-30
PCT/IB2001/001429 WO2002017918A2 (en) 2000-08-30 2001-08-08 Sustained release formulations for growth hormone secretagogues

Publications (1)

Publication Number Publication Date
AU2001276608A1 true AU2001276608A1 (en) 2002-03-13

Family

ID=22859744

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001276608A Abandoned AU2001276608A1 (en) 2000-08-30 2001-08-08 Sustained release formulations for growth hormone secretagogues

Country Status (19)

Country Link
US (2) US6641840B2 (en)
EP (1) EP1313473A2 (en)
JP (1) JP2004507502A (en)
AP (1) AP2001002264A0 (en)
AR (2) AR035195A1 (en)
AU (1) AU2001276608A1 (en)
BR (1) BR0113626A (en)
CA (1) CA2420535A1 (en)
DO (1) DOP2001000241A (en)
GT (1) GT200100175A (en)
HN (1) HN2001000190A (en)
MX (1) MXPA03001771A (en)
PA (1) PA8526101A1 (en)
PE (1) PE20020584A1 (en)
SV (1) SV2002000615A (en)
TN (1) TNSN01130A1 (en)
TW (1) TW200412955A (en)
UY (1) UY26910A1 (en)
WO (1) WO2002017918A2 (en)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
EP1448235B1 (en) * 2001-11-30 2007-03-14 Pfizer Products Inc. Oral controlled release pharmaceutical compositions of 5,8,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20050279827A1 (en) * 2004-04-28 2005-12-22 First Data Corporation Methods and systems for providing guaranteed merchant transactions
US20060093560A1 (en) * 2004-10-29 2006-05-04 Jen-Chi Chen Immediate release film coating
US20070184111A1 (en) * 2006-02-03 2007-08-09 Pharmavite Llc Hybrid tablet
BRPI0710914A2 (en) * 2006-04-24 2011-09-27 Pfizer Prod Inc dosage form and method for the treatment of nicotine addiction, addiction and suppression, in particular for use in smoking cessation therapy
CA2666149A1 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
PT2118123E (en) 2007-01-31 2016-02-10 Harvard College Stabilized p53 peptides and uses thereof
HUE031070T2 (en) 2007-03-15 2017-06-28 Auspex Pharmaceuticals Inc DEUTERATED d9-VENLAFAXINE
KR101623985B1 (en) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Stitched polypeptides
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
BRPI0816798A2 (en) 2007-09-11 2016-10-11 Activx Biosciences Inc compound, pharmaceutical composition, methods for inhibiting the action of glycogen synthase kinase-3, and for treating, preventing or ameliorating a disease, use of a compound, and article of manufacture
EP2203459B1 (en) 2007-09-12 2016-03-16 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as gsk-3 inhibitors
CN101820863A (en) * 2007-10-10 2010-09-01 马林克罗特贝克公司 Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
PL2947072T3 (en) 2008-03-17 2017-05-31 Ambit Biosciences Corporation 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea as raf kinase modulator in the treatment of cancer diseases
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
NZ594661A (en) 2009-02-27 2013-11-29 Ambit Biosciences Corp Jak kinase modulating quinazoline derivatives and methods of use thereof
EP2403860B1 (en) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
MX2011009413A (en) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment.
EP2411387B1 (en) 2009-03-27 2015-08-19 VetDC, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
MX2011011139A (en) 2009-04-22 2012-01-27 Axikin Pharmaceuticals Inc 2,5-disubstituted arylsulfonamide ccr3 antagonists.
CN102459177B (en) 2009-04-22 2015-09-02 埃克希金医药品有限公司 The dibasic Arylsulfonamide ccr 3 antagonists of 2,5-
HUE025647T2 (en) 2009-04-22 2016-04-28 Axikin Pharmaceuticals Inc Arylsulfonamide CCR3 antagonists
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
EP2451802A1 (en) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
HUE035519T2 (en) 2009-07-08 2018-05-02 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
KR20120099378A (en) 2009-08-14 2012-09-10 닛뽕 케미파 가부시키가이샤 Use of ppar delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases
US8470817B2 (en) 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
ES2654147T3 (en) 2009-11-16 2018-02-12 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
US8362068B2 (en) 2009-12-18 2013-01-29 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
US8999995B2 (en) 2010-03-02 2015-04-07 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
SG183993A1 (en) * 2010-03-09 2012-10-30 Alkermes Pharma Ireland Ltd Alcohol resistant enteric pharmaceutical compositions
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
CN102821775B (en) * 2010-03-15 2014-10-22 益普生制药股份有限公司 Pharmaceutical compositions of growth hormone secretagogue receptor ligands
AR080770A1 (en) 2010-03-17 2012-05-09 Axikin Pharmaceuticals Inc PIPERIDINSULFONAMIDS MODULATORS OF THE ACTIVITY OF XCC3 RECEPTORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USE OF THE SAME IN THE TREATMENT OF RESPIRATORY PATHOLOGIES, SUCH AS ASTHMA, AMONG OTHER.
JP6019015B2 (en) 2010-06-01 2016-11-02 ビオトヘルイク， インコーポレイテッド Method for treating hematological malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2 (1H) -pyridone
CN104945318A (en) 2010-06-01 2015-09-30 拜欧赛里克斯公司 Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
CA2801778C (en) 2010-06-07 2018-06-05 Novomedix, Llc Furanyl compounds and the use thereof
CA2805745C (en) 2010-07-19 2019-01-15 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
PT2603600T (en) 2010-08-13 2019-02-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
WO2012030910A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
EP2611794A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
JP5932794B2 (en) 2010-09-01 2016-06-08 アムビト ビオスシエンセス コルポラチオン Optically active pyrazolylaminoquinazoline, pharmaceutical composition thereof and method of use
EP2611809A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
US8633207B2 (en) 2010-09-01 2014-01-21 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
WO2012030885A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
WO2012030918A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
US20130296363A1 (en) 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
WO2012030894A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2012051090A1 (en) 2010-10-11 2012-04-19 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
US20140079686A1 (en) 2010-12-06 2014-03-20 Shikha P. Barman Methods For Treating Baldness And Promoting Hair Growth
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
AR085352A1 (en) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc MACROCICLIC INHIBITORS OF SERINA PROTEASA, ITS PHARMACEUTICAL COMPOSITIONS AND ITS USE TO TREAT HCV INFECTIONS
US20140088103A1 (en) 2011-03-28 2014-03-27 Mei Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
CN107501241B (en) 2011-03-28 2020-10-13 梅制药公司 Compounds, pharmaceutical compositions containing them and their use in the treatment of proliferative diseases
BR112013024909A2 (en) 2011-03-28 2019-09-24 Mei Pharma Inc compound, pharmaceutical composition, method for treating, preventing or ameliorating one or more symptoms of pi3k-mediated disorder, disease, or condition, and method for modulating pi3k enzymatic activity
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
SG2014014419A (en) 2011-09-13 2014-07-30 Pharmacyclics Inc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
CN104039342A (en) 2011-10-18 2014-09-10 爱勒让治疗公司 Peptidomimetic macrocyles
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
EP2822572B1 (en) 2012-02-15 2020-06-10 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
SG11201405761WA (en) 2012-03-16 2014-10-30 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
WO2014039748A1 (en) 2012-09-07 2014-03-13 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide ccr3 antagonists
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
BR112015009470A2 (en) 2012-11-01 2019-12-17 Aileron Therapeutics Inc disubstituted amino acids and their methods of preparation and use
US20150272924A1 (en) 2012-11-08 2015-10-01 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
MX370519B (en) 2012-11-30 2019-12-17 Novomedix Llc Substituted biaryl sulfonamides and the use thereof.
EP2943188A1 (en) 2013-01-11 2015-11-18 Mayo Foundation for Medical Education and Research Vitamins c and k for treating polycystic diseases
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015051336A1 (en) 2013-10-03 2015-04-09 David Wise Compositions and methods for treating pelvic pain and other conditions
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
AU2015231215B2 (en) 2014-03-20 2019-07-18 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
DK3119762T3 (en) 2014-03-20 2021-08-30 Capella Therapeutics Inc BENZIMIDAZOLE DERIVATIVES AS ERBB-TYROSINE CHINASE INHIBITORS FOR THE TREATMENT OF CANCER
HUE060851T2 (en) 2014-04-17 2023-04-28 Ketabon Gmbh Oral dosage form of ketamine
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
MX2017008526A (en) 2014-12-23 2017-10-25 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors.
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN107921032B (en) 2015-06-23 2021-09-24 纽罗克里生物科学有限公司 Inhibitors of VMAT2 for use in treating neurological diseases or disorders
CN115304596A (en) 2015-10-30 2022-11-08 纽罗克里生物科学有限公司 VALBENAZINE salts and polymorphs thereof
RS63170B1 (en) 2015-12-23 2022-05-31 Neurocrine Biosciences Inc Synthetic method for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]lsoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
EP3442940A1 (en) 2016-04-11 2019-02-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
TWI753910B (en) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease
MA46285A (en) 2016-09-19 2019-07-31 Mei Pharma Inc POLYTHERAPY
CN116987014A (en) 2016-11-09 2023-11-03 诺沃梅迪科斯有限公司 Nitrite salts of 1, 1-metformin, pharmaceutical compositions and methods of use
CN110191705A (en) 2016-12-01 2019-08-30 亚尼塔公司 The method for the treatment of cancer
TW201827051A (en) 2016-12-02 2018-08-01 美商神經性分泌生物科學公司 Use of valbenazine for treating schizophrenia or schizoaffective disorder
KR20190108146A (en) 2017-01-27 2019-09-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 How do I administer certain VMAT2 inhibitors?
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
CA3057089A1 (en) * 2017-03-21 2018-09-27 Synthetic Biologics, Inc. Alkaline phosphatase formulations
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (en) 2017-05-09 2019-09-22 Cardix Therapeutics LLC Pharmaceutical compositions and methods of treating cardiovascular diseases
US11723883B2 (en) 2017-06-23 2023-08-15 Ketabon Gmbh Hydroxynorketamine for the use in the treatment of depression
WO2019060322A2 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
WO2019074492A1 (en) 2017-10-10 2019-04-18 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
EP3737750A4 (en) 2018-01-09 2021-11-17 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
CA3087856A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
MX2020008375A (en) 2018-02-08 2020-09-25 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use.
CA3094173A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
CN112638387A (en) 2018-06-14 2021-04-09 纽罗克里生物科学有限公司 VMAT2 inhibitor compounds, compositions, and methods related thereto
EP3836926A4 (en) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
AU2020288163A1 (en) 2019-06-03 2022-01-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Non-hygroscopic crystalline salts of a pyrazole compound, and pharmaceutical compositions and use thereof
CA3146157A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
CA3146159A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
WO2021021563A1 (en) 2019-07-26 2021-02-04 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
WO2021059023A1 (en) 2019-09-26 2021-04-01 Abionyx Pharma Sa Compounds useful for treating liver diseases
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
CA3201965A1 (en) 2020-12-14 2022-06-23 Kyle W.H. Chan Pde4 degraders, pharmaceutical compositions, and therapeutic applications
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
AU2022292649A1 (en) 2021-06-16 2024-01-04 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022266249A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2023220640A1 (en) 2022-05-10 2023-11-16 Biotheryx, Inc. Cdk protein degraders, pharmaceutical compositions, and therapeutic applications

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672059A1 (en) * 1992-11-18 1995-09-20 The Du Pont Merck Pharmaceutical Company CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa
RO115804B1 (en) 1992-12-11 2000-06-30 Merck & Co Inc Spiropyperidine derivatives, processes for preparation and pharmaceutical compositions thereof
AU690941B2 (en) 1993-11-15 1998-05-07 Celtrix Pharmaceuticals, Inc. Method of treating renal disease by administering IGF-I and IGFBP-3
ES2163504T5 (en) 1994-05-06 2008-05-16 Pfizer Inc. DOSAGE FORMS OF CONTROLLED AZITROMYCIN RELEASE.
US5840331A (en) 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin
EP0761220A1 (en) 1995-08-21 1997-03-12 Eli Lilly And Company 2-Acylaminopropanamides as growth hormone secretagogues
EA199800337A1 (en) 1995-10-27 1998-10-29 Мерк Энд Ко., Инк. METHOD OF OBTAINING GROWTH HORMONE GROWTH STRENGTHEN THE SECRETION
JPH11513989A (en) * 1995-10-27 1999-11-30 メルク エンド カンパニー インコーポレーテッド Wet granulation of growth hormone secretagogue
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US5948757A (en) 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US5919777A (en) 1996-04-24 1999-07-06 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6071926A (en) 1996-05-22 2000-06-06 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
US5817627A (en) 1996-06-14 1998-10-06 Theratechnologies Inc. Long-acting galenical formulation for GRF peptides
US5945412A (en) 1996-12-09 1999-08-31 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
UA53716C2 (en) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. A substituted dipeptide tartaric salt as an agent stimulating the growth hormone secretion
US6251902B1 (en) 1997-06-25 2001-06-26 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
PL337806A1 (en) 1997-07-01 2000-09-11 Pfizer Sertralin salts and sertalin dosage forms of prolonged release
TR199903282T2 (en) 1997-07-01 2000-08-21 Pfizer Products Inc. Solution dosage form of sertraline encapsulated with gelatin.
JP3786715B2 (en) 1997-07-01 2006-06-14 ファイザー・プロダクツ・インク Delayed release dosage form of sertraline
TR199903297T2 (en) 1997-07-01 2000-07-21 Pfizer Products Inc. ��z�lm�� sertraline bi�imleri.
AU1384799A (en) 1997-11-07 1999-05-31 Chiron Corporation Novel igf-i composition and its use
OA11569A (en) * 1998-06-16 2004-07-01 Pfizer Prod Inc Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty.
HN1999000097A (en) * 1998-06-16 1999-11-03 Pfizer Prod Inc COMBINATION THERAPY FOR MUSCOLOSKELETAL FRAGILITY
WO2000012047A2 (en) 1998-09-02 2000-03-09 Merck & Co., Inc. Enhancement of return to independent living status with a growth hormone secretagogue
EP2311442A1 (en) * 1998-11-02 2011-04-20 Elan Pharma International Limited Multiparticulate modified release composition

Also Published As

Publication number Publication date
WO2002017918A3 (en) 2002-07-25
US20020137765A1 (en) 2002-09-26
EP1313473A2 (en) 2003-05-28
PA8526101A1 (en) 2002-07-30
AR035195A1 (en) 2004-05-05
TW200412955A (en) 2004-08-01
US6641840B2 (en) 2003-11-04
CA2420535A1 (en) 2002-03-07
AR042937A2 (en) 2005-07-06
GT200100175A (en) 2002-04-22
AP2001002264A0 (en) 2001-09-30
MXPA03001771A (en) 2003-06-04
BR0113626A (en) 2003-06-17
HN2001000190A (en) 2001-10-08
TNSN01130A1 (en) 2005-11-10
JP2004507502A (en) 2004-03-11
SV2002000615A (en) 2002-10-24
PE20020584A1 (en) 2002-07-06
WO2002017918A2 (en) 2002-03-07
US20040091530A1 (en) 2004-05-13
DOP2001000241A (en) 2003-05-31
UY26910A1 (en) 2002-03-22

Similar Documents

Publication Publication Date Title
AU2001276608A1 (en) Sustained release formulations for growth hormone secretagogues
HK1216613A1 (en) Controlled release hydrocodone formulations
GB0025208D0 (en) Delayed release pharmaceutical formulations
AU6606601A (en) Growth hormone secretagogues
EP1356809A4 (en) Sustained release preparations
AU2002229140A1 (en) Controlled release pharmaceutical composition
GB0100658D0 (en) Crystallisation - resistant aqueous growth hormone formulations
AU2001287977A1 (en) Controlled release formulations for oral administration
AU2001264264A1 (en) Sustained release compositions
IL147253A0 (en) Growth hormone formulations
AU2001246861A1 (en) Sustained release preparations
AU2001248772A1 (en) Sustained release drug compositions
IL144350A0 (en) Growth hormone secretagogues
AUPQ579800A0 (en) Plant growth hormone compositions
IL148908A0 (en) Oral controlled release formulations
AUPP279698A0 (en) Sustained release formulation
AU2001296389A1 (en) Stable peptide formulations
AU2001241187A1 (en) Sustained release oral preparations
AU2275700A (en) Sustained release composition comprising insuline like growth factor
GB9916958D0 (en) Controlled release formulations
GB0011333D0 (en) Controlled release formulations
HK1056555A1 (en) Growth hormone secretagogues
GB9916252D0 (en) Growth hormone formulation
AU2002219534A1 (en) Sustained release preparations
SI1216032T1 (en) Oral controlled release formulations